Case number 2015-2021
Endo Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Apr 23, 2021 | 0 | ENDO PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. [OPINION] [nonprecedential] (0) |
| Apr 23, 2021 | 0 | ENDO PHARMACEUTICALS INC. v. TEVA PHARMACEUTICALS USA, INC. [ORDER] [nonprecedential] (0) |
| Mar 7, 2019 | 246 | RESPONSE of Cross-Appellants Grunenthal Gmbh, Endo Pharmaceuticals Inc. and Appellants Impax Laboratories, Inc., ThoRx Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Barr Laboratories, Inc., Actavis South Atlantic LLC, Actavis Inc. and Watson Pharmaceuticals, Inc. to the court order [245] , court order [245]. Service: 03/07/2019 by email. [591025] [15-2021] [Charles Lipsey] [Entered: 03/07/2019 09:59 AM] (5) |
| Mar 7, 2019 | 247 | ORDER dismissing appeals; issuing mandate. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [591239] [15-2021, 15-2024, 15-2026, 15-2031] [JAB] [Entered: 03/07/2019 03:43 PM] (2) |
| Feb 21, 2019 | 245 | ORDER filed to show cause. Joint response to the show cause order is due on or before 03/07/2019. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [587757] [JAB] [Entered: 02/21/2019 04:10 PM] (2) |
| Oct 26, 2018 | 244 | Notice from Cross-Appellant Grunenthal Gmbh pursuant to Fed. R. App. P. 12.1(b) of district court's recent ruling on Grunenthal's Motion to Vacate. Service: 10/26/2018 by email. [560608] [15-2021] [Erin Sommers] [Entered: 10/26/2018 11:21 AM] (14) |
| Jun 29, 2018 | 243 | ORDER filed. The dismissal of Grünenthal’s appeals is vacated and the appeals are reinstated. The appeals are remanded to the district court for the limited purpose of its consideration of Grünenthal’s motion for vacatur. The court retains jurisdiction so that any of the parties may seek appellate review by notifying the Clerk of the Court within thirty days of entry of the district court’s decision on remand. Grünenthal’s appeals are held in abeyance pending the resolution of its motion for vacatur by the district court. Grünenthal’s conditional motions [239], [242] and Kashiv’s motion [237] are denied. By: Merits Panel (Per Curiam). Service as of this date by the Clerk of Court. [532702] [15-2021, 15-2022, 15-2023, 15-2024, 15-2025, 15-2026, 15-2028, 15-2031, 15-2033, 15-2034, 15-2035, 15-2041, 15-2042, 15-2046, 15-2047, 15-2049, 15-2059, 15-2060, 16-1025, 16-1060, 16-1117, 16-1118] [JAB] [Entered: 06/29/2018 09:37 AM] (3) |
| Jun 22, 2018 | 242 | MOTION of Cross-Appellant Grunenthal Gmbh to extend the time to file a Combined Petition for Panel Rehearing and Rehearing En Banc until 07/13/2018 [Consent: not addressed]. Service: 06/22/2018 by email. [531502] [15-2021] [Charles Lipsey] [Entered: 06/22/2018 03:17 PM] (10) |
| Jun 15, 2018 | 241 | REPLY of Kashiv Pharma, LLC to response filed by Cross-Appellant, Doc. No [240]. Service: 06/15/2018 by email. [530043] [15-2021] [Charles Weiss] [Entered: 06/15/2018 05:26 PM] (34) |
| Jun 11, 2018 | 240 | RESPONSE of Cross-Appellant Grunenthal Gmbh to the motion for leave to intervene [237]. Service: 06/11/2018 by email. [528576] [15-2021] [Charles Lipsey] [Entered: 06/11/2018 11:22 PM] (94) |
| Jun 8, 2018 | 239 | MOTION of Cross-Appellant Grunenthal Gmbh to extend the time to file a Combined Petition for Panel Rehearing and Rehearing En Banc until 06/29/2018 [Consent: partial consent]. Service: 06/08/2018 by email. [528191] [15-2021] [Charles Lipsey] [Entered: 06/08/2018 05:44 PM] (7) |
| Jun 4, 2018 | 237 | MOTION of Kashiv Pharma, LLC for leave to intervene [Consent: opposed]. Service: 06/04/2018 by email. [526538] [15-2021] [Charles Weiss] [Entered: 06/04/2018 09:51 AM] (31) |
| Jun 4, 2018 | 238 | Entry of appearance for Katie Crosby Lehmann as of counsel for Kashiv Pharma, LLC. Service: 06/04/2018 by email. [526716] [15-2021] [Katie Crosby Lehmann] [Entered: 06/04/2018 03:45 PM] (5) |
| Jun 1, 2018 | 235 | Entry of appearance for Charles A. Weiss as principal counsel for Kashiv Pharma, LLC.. Service: 06/01/2018 by email. [526454] [15-2021] [Charles Weiss] [Entered: 06/01/2018 06:40 PM] (1) |
| Jun 1, 2018 | 236 | Entry of appearance for Charles A. Weiss as principal counsel for Kashiv Pharma, LLC.. Service: 06/01/2018 by email. [526460] [15-2021] [Charles Weiss] [Entered: 06/01/2018 07:27 PM] (35) |
| May 25, 2018 | 233 | MOTION of to vacate the judgments from the SDNY with respect to the issues related to U.S. Patent Nos. 8,114,383 and 8,309,060 and remand to the district court with instructions to dismiss all claims and defenses relating to the GRT patents consistent with vacatur in U.S. District Court for the Southern District of New York Case Nos. 1:12-cv-08060-TPG-GWG, 1:12-cv-08317-TPG-GWG, 1:13-cv-00435-TPG-GWG, and 1:13-cv-0436-TPG. [Consent: not addressed]. Service: 05/25/2018 by email. [524873] [15-2021] [Charles Lipsey] [Entered: 05/25/2018 05:22 PM] (20) |
| May 25, 2018 | 234 | Sealed or confidential document received [Plaintiff-Cross-Appellant Grunenthal's Motion to Vacate] (corresponding to Doc No. [233]) for Cross-Appellant Grunenthal Gmbh. Service: 05/25/2018 by email. [524875] [15-2021] [Charles Lipsey] [Entered: 05/25/2018 05:30 PM] (0) |
| May 16, 2018 | 232 | OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. The motions [215], [217], [220], and [226] are granted; Appeal Nos. 15-2022, 15-2023, 15-2025, 15-2028, 15-2033, 15-2034, 15-2035, 15-2041, 15-2042, 15-2047, 15-2049, 15-2059, 15-2060, and 16-1118 are voluntarily dismissed. Appeal Nos. 15-2021, 15-2024, 15-2026, and 15-2031 are dismissed. (Nonprecedential Opinion). (For the Court: Moore, Circuit Judge; Bryson, Circuit Judge and Hughes, Circuit Judge). [522062] [15-2021, 15-2022, 15-2023, 15-2024, 15-2025, 15-2026, 15-2028, 15-2031, 15-2033, 15-2034, 15-2035, 15-2041, 15-2042, 15-2046, 15-2047, 15-2049, 15-2059, 15-2060, 16-1025, 16-1060, 16-1117, 16-1118] Vacated-in-part pursuant to the court's order. See Doc. No. [243]. [JAB] [Entered: 05/16/2018 09:51 AM] (28) |
| Apr 26, 2018 | 230 | Status report for Cross-Appellant Grunenthal Gmbh. Service: 04/26/2018 by email. [517143] [15-2021] [Charles Lipsey] [Entered: 04/26/2018 03:40 PM] (3) |
| Mar 30, 2018 | 229 | RESPONSE of Cross-Appellant Endo Pharmaceuticals Inc. to the motion to terminate appeal [226] filed by Appellants Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc. and Sun Pharmaceutical Industries, Ltd.. Service: 03/30/2018 by email. [509573] [15-2021] [Martin Black] [Entered: 03/30/2018 01:23 PM] (11) |
| Mar 22, 2018 | 228 | Notice from Cross-Appellant Endo Pharmaceuticals Inc. Intent to File a Response to the Motion to Dismiss Filed by Appellants Ranbaxy, Inc., Ranbaxy Pharmaceuticals, Inc., and Sun Pharmaceutical Industries, Ltd.. Service: 03/22/2018 by email. [507201] [15-2021] [Martin Black] [Entered: 03/22/2018 02:48 PM] (3) |
| Mar 21, 2018 | 226 | MOTION of Appellants Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc. and Sun Pharmaceutical Industries, Ltd. to terminate appeal through Motion to Dismiss as Moot. [Consent: unopposed]. Service: 03/21/2018 by email. [506995] [15-2021] [William Zimmerman] [Entered: 03/21/2018 08:13 PM] (11) |
| Mar 21, 2018 | 227 | Sealed or confidential document received [CONFIDENTIAL MOTION OF DEFENDANTS-APPELLANTS RANBAXY, INC., RANBAXY PHARMACEUTICALS, INC., SUN PHARMACEUTICAL INDUSTRIES, LTD. TO DISMISS AS MOOT APPEALS FROM THE 13-cv-4343 and 13-cv-8597(SDNY) ACTIONS] (corresponding to Doc No. [226]) for Appellants Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc. and Sun Pharmaceutical Industries, Ltd.. Service: 03/21/2018 by email. [507001] [15-2021] [William Zimmerman] [Entered: 03/21/2018 08:21 PM] (0) |
| Feb 26, 2018 | 223 | RESPONSE of Cross-Appellant Endo Pharmaceuticals Inc. to the motion to terminate cross/consolidated appeal [217] filed by Appellants Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc., Watson Pharmaceuticals, Inc., Actavis South Atlantic LLC and Actavis Inc. in 15-2021 , motion to terminate cross/consolidated appeal [215] filed by Appellants Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC in 15-2021 , motion to terminate cross/consolidated appeal [220] filed by Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc. in 15-2021. Service: 02/26/2018 by email. [501161] [Martin Black] [Entered: 02/26/2018 04:38 PM] (14) |
| Feb 26, 2018 | 224 | Sealed or confidential document received [Confidential Plaintiff-Cross-Appellant Endo Pharmaceuticals Inc.'s Response to the Defendants-Appellants Motions to Dismiss and Cross-Motion to Dismiss Endo's Cross-Appeals] (corresponding to Doc No. [223]) for Cross-Appellant Endo Pharmaceuticals Inc.. Service: 02/26/2018 by email. [501162] [Martin Black] [Entered: 02/26/2018 04:39 PM] (0) |
| Feb 26, 2018 | 225 | Letter from Cross-Appellant Grunenthal Gmbh Status report regarding stay of appeals pending FDA agency action. Service: 02/26/2018 by email. [501197] [Charles Lipsey] [Entered: 02/26/2018 05:55 PM] (3) |
| Feb 22, 2018 | 222 | Notice from Cross-Appellant Endo Pharmaceuticals Inc. Intent to Respond to Motions to Dismiss. Service: 02/22/2018 by email. [500331] [Martin Black] [Entered: 02/22/2018 12:47 PM] (3) |
| Feb 21, 2018 | 220 | MOTION of Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc. to terminate cross/consolidated appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 02/21/2018 by email. [499990] [Scott Samay] [Entered: 02/21/2018 04:49 PM] (14) |
| Feb 21, 2018 | 221 | Sealed or confidential document received [(CONFIDENTIAL) MOTION OF DEFENDANTS-APPELLANTS IMPAX LABORATORIES, INC. AND THORX LABORATORIES, INC. TO DISMISS AS MOOT CERTAIN APPEALS FROM THE 12-CV-8317 (SDNY) AND 12-CV-435 (SDNY) ACTIONS] (corresponding to Doc No. [220]) for Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc.. Service: 02/21/2018 by email. [499998] [Scott Samay] [Entered: 02/21/2018 04:53 PM] (0) |
| Feb 16, 2018 | 219 | Notice from Cross-Appellant Endo Pharmaceuticals Inc. Intent to Respond to Motions to Dismiss. Service: 02/16/2018 by email. [498941] [Martin Black] [Entered: 02/16/2018 12:34 PM] (3) |
| Feb 15, 2018 | 215 | MOTION of Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC to terminate cross/consolidated appeal. Any response is due within 10 days of service [Consent: unopposed]. Service: 02/15/2018 by email. [498233] [Brenda Joly] [Entered: 02/15/2018 04:46 PM] (12) |
| Feb 15, 2018 | 216 | Sealed or confidential document received [Motion of Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmacuticals, LLC to terminate certain consolidated appeals] (corresponding to Doc No. [215]) for Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC. Service: 02/15/2018 by email. [498235] [Brenda Joly] [Entered: 02/15/2018 04:49 PM] (0) |
| Feb 15, 2018 | 217 | MOTION of Appellants Actavis Inc., Actavis South Atlantic LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc. and Watson Pharmaceuticals, Inc. to terminate cross/consolidated appeal. Any response is due within 10 days of service [Consent: partial consent]. Service: 02/15/2018 by email. [498247] [William Burgess] [Entered: 02/15/2018 05:10 PM] (9) |
| Feb 15, 2018 | 218 | Sealed or confidential document received [Joint Motion of Teva Pharmaceuticals USA, Inc., Barr Laboratories, Inc., Actavis Inc., Actavis South Atlantic LLC, and Watson Pharmaceuticals, Inc. to Dismiss Appeal Nos. 15-2034 and 15-2042 as Moot] (corresponding to Doc No. [217]) for Appellants Actavis Inc., Actavis South Atlantic LLC, Barr Laboratories, Inc., Teva Pharmaceuticals USA, Inc. and Watson Pharmaceuticals, Inc.. Service: 02/15/2018 by email. [498248] [William Burgess] [Entered: 02/15/2018 05:12 PM] (0) |
| Dec 5, 2017 | 211 | TENDERED from Cross-Appellant Endo Pharmaceuticals Inc.. Title: LETTER BRIEF. Service: 12/05/2017 by email. [480391] [Martin Black] [Entered: 12/05/2017 04:01 PM] (10) |
| Dec 5, 2017 | 212 | TENDERED from Cross-Appellant Endo Pharmaceuticals Inc.. Title: CONFIDENTIAL LETTER BRIEF Service: 12/05/2017 by US mail, email. [480392] [Martin Black] [Entered: 12/05/2017 04:03 PM] (0) |
| Dec 5, 2017 | 213 | BRIEF FILED (LETTER) of Cross-Appellant Endo Pharmaceuticals Inc. [211] Number of Pages: 2. Service: 12/05/2017 by email. [480522] [SJ] [Entered: 12/06/2017 10:15 AM] (10) |
| Dec 5, 2017 | 214 | CONFIDENTIAL BRIEF FILED (LETTER) of Cross-Appellant Endo Pharmaceuticals Inc. [212] Number of Pages: 2. Service: 12/05/2017 by US mail, email. [480525] [SJ] [Entered: 12/06/2017 10:17 AM] (0) |
| Dec 4, 2017 | 209 | Request from the merits panel at oral agrument: Cross-Appellant(s) should submit a 2-page single-spaced letter brief by COB tomorrow (12/5) that includes citations to the joint appendix demonstrating where the district court found substantial evidence of irreparable harm pertaining to lost earnings. [479896] [SJ] [Entered: 12/04/2017 01:10 PM] (0) |
| Dec 4, 2017 | 210 | Submitted after ORAL ARGUMENT by John C. O'Quinn for Actavis South Atlantic LLC, Actavis Inc., Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Barr Laboratories, Inc., Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc., and Watson Pharmaceuticals, Inc. and Martin Jay Black for Endo Pharmaceuticals Inc.. Panel: Judge: Moore, Judge: Bryson, Judge: Hughes. [480024] [SJ] [Entered: 12/04/2017 03:49 PM] (0) |
| Nov 16, 2017 | 207 | RESPONSE of Appellants Actavis Inc. and Actavis South Atlantic LLC to the supplemental authority [204] filed by Cross-Appellant Endo Pharmaceuticals Inc. in 15-2021. Service: 11/16/2017 by email. [476122] [William Burgess] [Entered: 11/16/2017 11:30 AM] (3) |
| Nov 16, 2017 | 208 | This entry was made in error and has been removed from the docket. [476148] [JAB] [Entered: 11/16/2017 12:24 PM] (0) |
| Nov 15, 2017 | 205 | Response to oral argument order from the Cross-Appellant Endo Pharmaceuticals Inc.. designating Martin J. Black as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [475937] [Martin Black] [Entered: 11/15/2017 04:32 PM] (0) |
| Nov 15, 2017 | 206 | Response to oral argument order from the Appellants Actavis Inc., Actavis South Atlantic LLC, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Barr Laboratories, Inc., Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc. and Watson Pharmaceuticals, Inc.. designating John C. O'Quinn as arguing attorney. Designated time for argument: 12 minutes. Designated time for rebuttal: 3 minutes. Service of other counsel by Notice of Docket Activity from this entry. [475962] [William Burgess] [Entered: 11/15/2017 05:27 PM] (0) |
| Nov 7, 2017 | 204 | Citation of Supplemental Authority pursuant to Fed. R. App. P. 28(j) for Cross-Appellant Endo Pharmaceuticals Inc.. Service: 11/07/2017 by email. [473732] [Martin Black] [Entered: 11/07/2017 01:54 PM] (22) |
| Oct 26, 2017 | 202 | NOTICE OF CALENDARING. Panel: 1712D. Case scheduled Dec 04, 2017 10:00 a.m. at the United States Court of Appeals for the Federal Circuit (Howard T. Markey National Courts Building, 717 Madison Place, N.W. Washington, DC 20439), Courtroom 203. Response to oral argument order due: 11/15/2017. Arguing counsel is required to check-in with the Clerk's Office, 4th Floor, Room 401, between 8:30 a.m. and 9:30 a.m. on the day of argument. Please review the Oral Argument Order. [470811] [JAB] [Entered: 10/26/2017 01:14 PM] (0) |
| Oct 26, 2017 | 203 | ORDER filed. The motion [197] filed by Cross-Appellant Grunenthal Gmbh is granted. Oral argument will proceed as scheduled for the remaining arguments unaffected by the motion to stay. By: Merits Panel (Per Curiam). Service as of this date by Clerk of Court. [470864] [JAB] [Entered: 10/26/2017 03:40 PM] (2) |
| Oct 25, 2017 | 201 | RESPONSE of Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc. to the motion to stay appeal [197] filed by Cross-Appellant Grunenthal Gmbh in 15-2021. Service: 10/25/2017 by email. [470650] [Scott Samay] [Entered: 10/25/2017 06:09 PM] (3) |
| Oct 17, 2017 | 197 | MOTION of Cross-Appellant Grunenthal Gmbh to stay appeal. Any response is due within 10 days of service [Consent: opposed]. Service: 10/17/2017 by email. [468624] [Charles Lipsey] [Entered: 10/17/2017 07:45 PM] (60) |
| Oct 17, 2017 | 198 | Sealed or confidential document received [Motion to Stay] (corresponding to Doc No. [197]) for Cross-Appellant Grunenthal Gmbh. Service: 10/17/2017 by email. [468625] [Charles Lipsey] [Entered: 10/17/2017 07:50 PM] (0) |
| Oct 17, 2017 | 199 | Amended Certificate of Interest for the Cross-Appellant Grunenthal Gmbh. Service: 10/17/2017 by email. [468626] [Charles Lipsey] [Entered: 10/17/2017 07:51 PM] (3) |
| Oct 17, 2017 | 200 | Notice from Appellants Actavis Inc. and Actavis South Atlantic LLC regarding conflicts with oral argument (Request not to schedule argument same week as nos. 17-1094, 17-1131, or companion cases 17-1575 + 17-1594). Service: 10/17/2017 by email. [468627] [John O'Quinn] [Entered: 10/17/2017 07:57 PM] (2) |
| Oct 13, 2017 | 196 | Amended Entry of appearance for Robert D. Rhoad as of counsel for Cross-Appellant Endo Pharmaceuticals Inc.. Service: 10/13/2017 by email. [467600] [Martin Black] [Entered: 10/13/2017 11:47 AM] (3) |
| Sep 11, 2017 | 195 | Notice from Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC regarding conflicts with oral argument (November 6, 8-9, 2017). Service: 09/11/2017 by email. [460235] [Brenda Joly] [Entered: 09/11/2017 05:38 PM] (1) |
| Sep 8, 2017 | 194 | Notice from Appellants Actavis Inc. and Actavis South Atlantic LLC regarding conflicts with oral argument (Request that the Court not schedule any two of 15-2021, 16-2099, 17-1094, and 17-1131 during the same argument week.). Service: 09/08/2017 by email. [459876] [John O'Quinn] [Entered: 09/08/2017 04:26 PM] (2) |
| Sep 6, 2017 | 193 | Notice from Cross-Appellant Endo Pharmaceuticals Inc. regarding conflicts with oral argument (November 7-9, 2017). Service: 09/06/2017 by email. [459026] [Martin Black] [Entered: 09/06/2017 03:12 PM] (3) |
| Jul 26, 2017 | 192 | Notice from Appellants Actavis Inc. and Actavis South Atlantic LLC regarding conflicts with oral argument (Request not to schedule argument during October court week (conflict with argument in No. 17-1499), or during the same week as appeal no. 17-1131 (see letter for details)). Service: 07/26/2017 by email. [449544] [John O'Quinn] [Entered: 07/26/2017 06:07 PM] (4) |
| Jul 13, 2017 | 190 | Notice from Cross-Appellant Endo Pharmaceuticals Inc. regarding conflicts with oral argument (September 5-8, 2017). Service: 07/13/2017 by email. [446126] [Martin Black] [Entered: 07/13/2017 10:20 AM] (3) |
| Jul 13, 2017 | 191 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account of Jamie R. Kurtz for Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC. The e-mail address, (dspence@robinskaplan.com), associated with your CM/ECF account has generated a delivery failure notice. Counsel should promptly report a change in contact information with the Pacer Service Center (see Fed. Cir. R. 47.3(c)(1). [446128] [PMM] [Entered: 07/13/2017 10:26 AM] (0) |
| Jul 6, 2017 | 189 | Notice from Appellants Actavis Inc. and Actavis South Atlantic LLC regarding conflicts with oral argument (Of appeal Nos. 15-2021, 17-1499, and 17-1131, request that no two be scheduled during the same argument week (see letter for details)). Service: 07/06/2017 by email. [444332] [John O'Quinn] [Entered: 07/06/2017 12:26 AM] (2) |
| Apr 19, 2017 | 188 | 6 paper copies of the Corrected Response Brief [184] received from Cross-Appellant Endo Pharmaceuticals Inc.. [425613] [KW] [Entered: 04/19/2017 03:11 PM] (0) |
| Apr 14, 2017 | 186 | Notice from Cross-Appellant Grunenthal Gmbh regarding conflicts with oral argument (July 10-14, 2017). Service: 04/14/2017 by email. [424086] [Charles Lipsey] [Entered: 04/14/2017 09:00 AM] (2) |
| Apr 14, 2017 | 187 | Notice from Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC regarding conflicts with oral argument (June 5-9, 2017). Service: 04/14/2017 by email. [424371] [Brenda Joly] [Entered: 04/14/2017 04:35 PM] (1) |
| Apr 13, 2017 | 185 | Notice from Cross-Appellant Endo Pharmaceuticals Inc. regarding conflicts with oral argument (June 9, 1017; July 10-14, 2017; and August 7-9, 2017). Service: 04/13/2017 by email. [423868] [Martin Black] [Entered: 04/13/2017 02:56 PM] (3) |
| Apr 12, 2017 | 183 | 6 paper copies of the Confidential Joint Appendix (Vol. I-V) [168] received from Appellants Actavis Inc., Actavis South Atlantic LLC, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, et al. [423510] [KW] [Entered: 04/12/2017 02:33 PM] (0) |
| Apr 11, 2017 | 180 | Notice from Appellants Actavis Inc. and Actavis South Atlantic LLC regarding conflicts with oral argument ((1) of appeal nos. 16-2099, 16-2563, and 15-2021, request that no two be scheduled during the same argument week; (2) unavailable August 7-9, 2017 (see letter)). Service: 04/11/2017 by email. [423120] [John O'Quinn] [Entered: 04/11/2017 12:20 PM] (1) |
| Apr 11, 2017 | 181 | Notice of Correction to the Brief Doc No. [129] for Cross-Appellant Endo Pharmaceuticals Inc.. Service: 04/11/2017 by email. [423267] [Martin Black] [Entered: 04/11/2017 04:36 PM] (5) |
| Apr 11, 2017 | 182 | TENDERED from Cross-Appellant Endo Pharmaceuticals Inc.. Title: CORRECTED RESPONSE BRIEF. Service: 04/11/2017 by email. [423268] [Martin Black] [Entered: 04/11/2017 04:38 PM] (194) |
| Apr 11, 2017 | 184 | CORRECTED BRIEF FILED for Cross-Appellant Endo Pharmaceuticals Inc. [182]. Number of Pages: 80. Service: 04/11/2017 by email. The paper copies of the brief should be received by the court on or before 04/20/2017. [423798] [FMS] [Entered: 04/13/2017 12:05 PM] (194) |
| Apr 7, 2017 | 170 | Notice to counsel: The record of this case indicates that the Certificate of Compliance with Fed. Cir. R. 11(d) has not been filed. IF any portion of the record in the trial court/agency is subject to a protective order, counsel should promptly file the appropriate Certificate of Compliance using the Cert of Compliance Modification of Protective Order (R11/17) event which is found in the Forms and Certificates category. Service as of this date by Clerk of Court. [422303] [JCA] [Entered: 04/07/2017 10:41 AM] (0) |
| Apr 7, 2017 | 171 | Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks (June 2017, July 2017, August 2017), or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 04/14/2017. [422304] [JCA] [Entered: 04/07/2017 10:41 AM] (0) |
| Apr 7, 2017 | 172 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC. Service: 04/07/2017 by email. [422338] [Brenda Joly] [Entered: 04/07/2017 11:29 AM] (3) |
| Apr 7, 2017 | 173 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc. and Sun Pharmaceutical Industries, Ltd.. Service: 04/07/2017 by email. [422419] [Carol Pitzel Cruz] [Entered: 04/07/2017 01:50 PM] (3) |
| Apr 7, 2017 | 174 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellant Grunenthal Gmbh. Service: 04/07/2017 by email. [422433] [Charles Lipsey] [Entered: 04/07/2017 02:16 PM] (3) |
| Apr 7, 2017 | 175 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellant Roxane Laboratories, Inc.. Service: 04/07/2017 by email. [422493] [Hugh Balsam] [Entered: 04/07/2017 03:30 PM] (3) |
| Apr 7, 2017 | 176 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Cross-Appellant Endo Pharmaceuticals Inc.. Service: 04/07/2017 by email. [422496] [Martin Black] [Entered: 04/07/2017 03:39 PM] (3) |
| Apr 7, 2017 | 177 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc.. Service: 04/07/2017 by email. [422560] [Scott Samay] [Entered: 04/07/2017 05:18 PM] (3) |
| Apr 7, 2017 | 178 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 04/07/2017 by email. [422561] [Brian Robinson] [Entered: 04/07/2017 05:24 PM] (3) |
| Apr 7, 2017 | 179 | Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellants Actavis Inc. and Actavis South Atlantic LLC. Service: 04/07/2017 by email. [422574] [William Burgess] [Entered: 04/07/2017 07:23 PM] (3) |
| Apr 6, 2017 | 163 | Statement of Compliance with Fed. Cir. R. 33 for Appellants Actavis Inc., Actavis South Atlantic LLC, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Barr Laboratories, Inc., Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc., Watson Pharmaceuticals, Inc. and Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh. Service: 04/06/2017 by email. [422213] [Brenda Joly] [Entered: 04/06/2017 05:10 PM] (6) |
| Apr 6, 2017 | 164 | TENDERED from Appellants Actavis Inc., Actavis South Atlantic LLC, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Barr Laboratories, Inc., Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc., Watson Pharmaceuticals, Inc. and Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh. Title: JOINT APPENDIX. Service: 04/06/2017 by email. [422224] [Brenda Joly] [Entered: 04/06/2017 06:15 PM] (2634) |
| Apr 6, 2017 | 165 | TENDERED from Appellants Actavis Inc., Actavis South Atlantic LLC, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Barr Laboratories, Inc., Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc., Watson Pharmaceuticals, Inc. and Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh. Title: JOINT APPENDIX. Service: 04/06/2017 by email. [422225] [Brenda Joly] [Entered: 04/06/2017 06:19 PM] (688) |
| Apr 6, 2017 | 166 | TENDERED from Appellants Actavis Inc., Actavis South Atlantic LLC, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Barr Laboratories, Inc., Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc., Watson Pharmaceuticals, Inc. and Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh. Title: CONFIDENTIAL JOINT APPENDIX Service: 04/06/2017 by email. [422227] [Brenda Joly] [Entered: 04/06/2017 06:27 PM] (0) |
| Apr 6, 2017 | 167 | TENDERED from Appellants Actavis Inc., Actavis South Atlantic LLC, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Barr Laboratories, Inc., Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc., Watson Pharmaceuticals, Inc. and Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh. Title: CONFIDENTIAL JOINT APPENDIX Service: 04/06/2017 by email. [422228] [Brenda Joly] [Entered: 04/06/2017 06:31 PM] (0) |
| Apr 6, 2017 | 168 | CONFIDENTIAL JOINT APPENDIX FILED for Actavis Inc., Actavis South Atlantic LLC, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Barr Laboratories, Inc., Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc. and Watson Pharmaceuticals, Inc. [167], [166]. Number of Pages: 3463. Service: 04/06/2017 by email. The paper copies of the confidential appendix should be received by the court on or before 04/14/2017. [422287] [JCA] [Entered: 04/07/2017 10:24 AM] (0) |
| Apr 6, 2017 | 169 | APPENDIX FILED for Actavis Inc., Actavis South Atlantic LLC, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Barr Laboratories, Inc., Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc. and Watson Pharmaceuticals, Inc. [165], [164]. Number of Pages: 3322. Service: 04/06/2017 by email. [422293] [JCA] [Entered: 04/07/2017 10:31 AM] (3322) |
| Mar 29, 2017 | 161 | 6 paper copies of the Reply Brief [160] received from Cross-Appellant Grunenthal Gmbh. [419985] [KW] [Entered: 03/29/2017 02:27 PM] (0) |
| Mar 29, 2017 | 162 | 6 paper copies of the Reply Brief [159] received from Cross-Appellant Endo Pharmaceuticals Inc. [420004] [KW] [Entered: 03/29/2017 02:52 PM] (0) |
| Mar 27, 2017 | 157 | TENDERED from Cross-Appellant Endo Pharmaceuticals Inc.. Title: REPLY BRIEF. Service: 03/27/2017 by email. [419261] [Martin Black] [Entered: 03/27/2017 04:57 PM] (71) |
| Mar 27, 2017 | 158 | TENDERED from Cross-Appellant Grunenthal Gmbh. Title: REPLY BRIEF. Service: 03/27/2017 by email. [419312] [Charles Lipsey] [Entered: 03/27/2017 07:10 PM] (43) |
| Mar 27, 2017 | 159 | REPLY BRIEF FILED for Cross-Appellant Endo Pharmaceuticals Inc. [157]. Number of Pages: 16. Service: 03/27/2017 by email. The paper copies of the brief should be received by the court on or before 04/04/2017. [419472] [SJ] [Entered: 03/28/2017 11:48 AM] (71) |
| Mar 27, 2017 | 160 | REPLY BRIEF FILED for Cross-Appellant Grunenthal Gmbh [158]. Number of Pages: 30. Service: 03/27/2017 by email. The paper copies of the brief should be received by the court on or before 04/04/2017. Appendix is due 04/06/2017. [419476] [SJ] [Entered: 03/28/2017 11:51 AM] (43) |
| Mar 9, 2017 | 156 | 6 paper copies of the Corrected Confidential Opening Brief [154] received from Appellants Actavis Inc. and Actavis South Atlantic LLC. [414493] [KW] [Entered: 03/10/2017 03:01 PM] (0) |
| Mar 6, 2017 | 152 | ORDER granting motion to correct document [141] filed by Appellants Actavis South Atlantic LLC and Actavis Inc.; granting motion to extend time to file reply brief [149] filed by Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh.; Six paper copies of the corrected confidential brief [142] are due within seven days of the date of this order. Service: 03/06/2017 by clerk. [412825] [NL] [Entered: 03/06/2017 04:28 PM] (2) |
| Mar 6, 2017 | 153 | 6 paper copies of the Joinder Brief [147] received from Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [413035] [KW] [Entered: 03/07/2017 01:51 PM] (0) |
| Mar 6, 2017 | 154 | CORRECTED CONFIDENTIAL BRIEF FILED for Appellants Actavis Inc. and Actavis South Atlantic LLC [142]. Number of Pages: 63. Service: 02/24/2017 by email. The paper copies of the brief should be received by the court on or before 03/16/2017. [413756] [SJ] [Entered: 03/09/2017 09:48 AM] (0) |
| Mar 6, 2017 | 155 | CORRECTED BRIEF FILED for Appellants Actavis Inc. and Actavis South Atlantic LLC [143]. Number of Pages: 63. Service: 02/24/2017 by email. [413762] [SJ] [Entered: 03/09/2017 09:57 AM] (335) |
| Mar 3, 2017 | 151 | 6 paper copies of the Reply Brief [144] received from Appellants Amneal Pharmaceuticals of New York, LLC, et al. [412444] [KW] [Entered: 03/03/2017 03:06 PM] (0) |
| Mar 2, 2017 | 150 | 6 paper copies of the Reply Brief [145] received from Appellants Actavis Inc. and Actavis South Atlantic LLC. [412258] [KW] [Entered: 03/03/2017 10:10 AM] (0) |
| Mar 1, 2017 | 149 | MOTION of Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh to extend the time to 03/27/2017 at 11:59 pm to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 03/01/2017 by email. [411699] [Charles Lipsey] [Entered: 03/01/2017 02:57 PM] (6) |
| Feb 28, 2017 | 148 | 6 paper copies of the Joinder Brief [146] received from Appellant Roxane Laboratories, Inc. [411527] [KW] [Entered: 03/01/2017 09:37 AM] (0) |
| Feb 24, 2017 | 141 | MOTION of Appellants Actavis Inc. and Actavis South Atlantic LLC to correct the Opening Brief [118], Opening Brief [117], Brief [101], confidential Brief [100]. Any response is due within 10 days of service [Consent: unopposed]. Service: 02/24/2017 by email. [410454] [William Burgess] [Entered: 02/24/2017 01:26 PM] (5) |
| Feb 24, 2017 | 142 | TENDERED from Appellants Actavis Inc. and Actavis South Atlantic LLC. Title: CORRECTED CONFIDENTIAL OPENING BRIEF Service: 02/24/2017 by email. [410457] [William Burgess] [Entered: 02/24/2017 01:27 PM] (0) |
| Feb 24, 2017 | 143 | TENDERED from Appellants Actavis Inc. and Actavis South Atlantic LLC. Title: CORRECTED OPENING BRIEF. Service: 02/24/2017 by email. [410458] [William Burgess] [Entered: 02/24/2017 01:28 PM] (335) |
| Feb 22, 2017 | 137 | TENDERED from Appellant Roxane Laboratories, Inc.. Title: REPLY BRIEF. Service: 02/22/2017 by email. [409778] [Alan Clement] [Entered: 02/22/2017 04:21 PM] (9) |
| Feb 22, 2017 | 138 | TENDERED from Appellants Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Sun Pharmaceutical Industries, Ltd. and ThoRx Laboratories, Inc.. Title: REPLY BRIEF. Service: 02/22/2017 by email. [409792] [Brenda Joly] [Entered: 02/22/2017 04:39 PM] (87) |
| Feb 22, 2017 | 139 | TENDERED from Appellants Actavis Inc. and Actavis South Atlantic LLC. Title: REPLY BRIEF. Service: 02/22/2017 by email. [409822] [William Burgess] [Entered: 02/22/2017 06:45 PM] (70) |
| Feb 22, 2017 | 140 | TENDERED from Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Title: NOTICE OF JOINDER. Service: 02/22/2017 by email. [409826] [Brian Robinson] [Entered: 02/22/2017 07:26 PM] (4) |
| Feb 22, 2017 | 144 | REPLY BRIEF FILED for Appellants Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Sun Pharmaceutical Industries, Ltd. and ThoRx Laboratories, Inc. [138]. Number of Pages: 70. Service: 02/22/2017 by email. The paper copies of the brief should be received by the court on or before 03/06/2017. [410905] [SJ] [Entered: 02/27/2017 03:07 PM] (87) |
| Feb 22, 2017 | 145 | REPLY BRIEF FILED for Appellants Actavis Inc. and Actavis South Atlantic LLC [139]. Number of Pages: 59. Service: 02/22/2017 by email. The paper copies of the brief should be received by the court on or before 03/06/2017. Cross-Appellant's reply brief is due 03/13/2017. [410915] [SJ] [Entered: 02/27/2017 03:12 PM] (70) |
| Feb 22, 2017 | 146 | Notice of Joinder for Appellant Roxane Laboratories, Inc. [137] joining in part IV [145] Reply Brief submitted by Appellants Actavis South Atlantic LLC and Actavis Inc. in 15-2021 , parts I-III [144] Reply Brief submitted by Appellants Impax Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Amneal Pharmaceuticals, LLC, Amneal Pharmaceuticals of New York, LLC and ThoRx Laboratories, Inc. in 15-2021. Service: 02/22/2017 by email. The paper copies of the brief should be received by the court on or before 03/06/2017 [410920] [SJ] [Entered: 02/27/2017 03:19 PM] (9) |
| Feb 22, 2017 | 147 | Notice of Joinder for Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [140] joining in [145] Reply Brief submitted by Appellants Actavis South Atlantic LLC and Actavis Inc. in 15-2021. Service: 02/22/2017 by email. The paper copies of the brief should be received by the court on or before 03/06/2017 [410923] [SJ] [Entered: 02/27/2017 03:23 PM] (4) |
| Dec 29, 2016 | 136 | **TEXT ONLY** ORDER granting motion to extend time to file reply briefs [135] filed by Appellants Actavis South Atlantic LLC and Actavis Inc. The reply briefs for all appellants are due 02/22/2017. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [395046] [AT] [Entered: 12/29/2016 11:18 AM] (0) |
| Dec 28, 2016 | 135 | MOTION of Appellants Actavis Inc. and Actavis South Atlantic LLC to extend the time to 02/22/2017 to file the reply brief. Any response is due within 10 days of service [Consent: unopposed]. Service: 12/28/2016 by email. [394945] [William Burgess] [Entered: 12/28/2016 08:46 PM] (7) |
| Dec 19, 2016 | 134 | 6 paper copies of the Response Brief [132] received from Cross-Appellant Endo Pharmaceuticals Inc. [392282] [KW] [Entered: 12/19/2016 02:00 PM] (0) |
| Dec 16, 2016 | 133 | 6 paper copies of the Opening Response Brief [132] received from Cross-Appellant Grunenthal Gmbh. [391877] [JCP] [Entered: 12/16/2016 01:38 PM] (0) |
| Dec 14, 2016 | 129 | TENDERED from Cross-Appellant Endo Pharmaceuticals Inc.. Title: RESPONSE BRIEF. Service: 12/14/2016 by email. [391128] This brief has been replaced. See Doc No. [184] [Martin Black] [Entered: 12/14/2016 05:50 PM] (0) |
| Dec 14, 2016 | 130 | TENDERED from Cross-Appellant Grunenthal Gmbh. Title: RESPONSE BRIEF. Service: 12/14/2016 by email. [391146] [Charles Lipsey] [Entered: 12/14/2016 08:03 PM] (81) |
| Dec 14, 2016 | 131 | BRIEF FILED for Cross-Appellant Endo Pharmaceuticals Inc. [129]. Number of Pages: 80. Service: 12/14/2016 by email. The paper copies of the brief should be received by the court on or before 12/20/2016. [391369] This brief has been replaced. See Doc No. [184] [AT] [Entered: 12/15/2016 12:51 PM] (0) |
| Dec 14, 2016 | 132 | BRIEF FILED for Cross-Appellant Grunenthal Gmbh [130]. Number of Pages: 66. Service: 12/14/2016 by email. The paper copies of the brief should be received by the court on or before 12/20/2016. Appellants' reply briefs are due 01/23/2017. [391371] [AT] [Entered: 12/15/2016 12:56 PM] (81) |
| Dec 12, 2016 | 128 | Entry of appearance for Krista E. Bianco as of counsel for Cross-Appellant Grunenthal Gmbh. Service: 12/12/2016 by email. [390210] [Krista Bianco] [Entered: 12/12/2016 04:56 PM] (2) |
| Oct 21, 2016 | 126 | MOTION of Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh to extend the time to 12/14/2016 at 11:59 pm to file the appellee/respondent/cross-appellant's principal brief. Response/Opposition is due 11/03/2016 [Consent: unopposed]. Service: 10/21/2016 by email. [376720] [Jennifer Roscetti] [Entered: 10/21/2016 03:42 PM] (13) |
| Oct 21, 2016 | 127 | **TEXT ONLY** ORDER granting motion to extend time to file appellee/respondent/cross-appellant principal brief [126] filed by Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh. Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh brief due 12/14/2016. Service as of this date by Clerk of Court. This order has been issued without an attached document and is official and binding. [376760] [JCA] [Entered: 10/21/2016 04:47 PM] (0) |
| Oct 11, 2016 | 124 | 6 paper copies of the Confidential Opening Brief [118] received from Appellants Actavis Inc. and Actavis South Atlantic LLC. [373128] [KW] [Entered: 10/11/2016 02:44 PM] (0) |
| Oct 11, 2016 | 125 | 6 paper copies of the Corrected Opening Brief [121] received from Appellants Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd. and ThoRx Laboratories, Inc. [373201] [KW] [Entered: 10/11/2016 04:10 PM] (0) |
| Oct 7, 2016 | 122 | 6 paper copies of the Notice of Joinder [119] received from Appellant Watson Pharmaceuticals, Inc. [372775] [JCP] [Entered: 10/07/2016 04:01 PM] (0) |
| Oct 7, 2016 | 123 | 6 paper copies of the Notice of Joinder [120] received from Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [372777] [JCP] [Entered: 10/07/2016 04:04 PM] (0) |
| Oct 5, 2016 | 114 | NOTICE OF REJECTION: The brief of Appellants Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd. and ThoRx Laboratories, Inc., Appellants Opening Brief [104], is not in compliance with the rules of this court and is therefore rejected for filing. See attached notice for explanation. Appellants' corrected brief is due 10/19/2016. Service as of this date by Clerk of Court. [371808] [AT] [Entered: 10/05/2016 12:29 PM] (1) |
| Oct 5, 2016 | 115 | TENDERED from Appellants Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd. and ThoRx Laboratories, Inc.. Title: CORRECTED OPENING BRIEF. Service: 10/05/2016 by email. [371910] [Brenda Joly] [Entered: 10/05/2016 02:48 PM] (378) |
| Oct 5, 2016 | 116 | ORDER filed. The motion [99] is granted. Actavis’s confidential and non-confidential briefs filed on July 29, 2016 in 2016-1025 (ECF Nos. 63 & 64 in 2016-1025 and ECF Nos. 85 & 86 in 2015-2021) will not be transmitted to the merits panel assigned to hear these cases. Service: 10/05/2016 by clerk. [371923] [15-2021, 16-1025] [LMS] [Entered: 10/05/2016 03:03 PM] (2) |
| Oct 5, 2016 | 117 | BRIEF FILED for Appellants Actavis Inc. and Actavis South Atlantic LLC [101]. Number of Pages: 63. Service: 09/30/2016 by email. The paper copies of the confidential version of the brief should be received by the court on or before 10/11/2016. [372046] This brief has been corrected. See Doc. No. [155] [AT] [Entered: 10/06/2016 08:13 AM] (0) |
| Oct 5, 2016 | 118 | CONFIDENTIAL BRIEF FILED for Appellants Actavis Inc. and Actavis South Atlantic LLC [100]. Number of Pages: 63. Service: 09/30/2016 by US mail. The paper copies of the brief should be received by the court on or before 10/11/2016. [372047] This brief has been corrected. See Doc. No. [154] [AT] [Entered: 10/06/2016 08:15 AM] (0) |
| Oct 5, 2016 | 119 | Notice of Joinder for Appellant Watson Pharmaceuticals, Inc. [102] joining in [118], [117] Opening Briefs submitted by Appellants Actavis South Atlantic LLC and Actavis Inc. in 15-2021. Service: 09/30/2016 by email. The paper copies of the joinder should be received by the court on or before 10/11/2016 [372050] [AT] [Entered: 10/06/2016 08:21 AM] (4) |
| Oct 5, 2016 | 120 | Notice of Joinder for Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc. [103] joining in [118] [117] Opening Briefs submitted by Appellants Actavis South Atlantic LLC and Actavis Inc. in 15-2021. Service: 10/03/2016 by email. The paper copies of the joinder should be received by the court on or before 10/11/2016 [372051] [AT] [Entered: 10/06/2016 08:25 AM] (4) |
| Oct 5, 2016 | 121 | CORRECTED BRIEF FILED for Appellants Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd. and ThoRx Laboratories, Inc. [115]. Number of Pages: 73. Service: 10/05/2016 by email. The paper copies of the brief should be received by the court on or before 10/11/2016. Cross-Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh brief is due 11/14/2016. [372065] [AT] [Entered: 10/06/2016 08:59 AM] (378) |
| Oct 4, 2016 | 108 | NOTICE OF DEFICIENCY: The attorney entry of appearance for SCOTT R. SAMAY Document No. [107] filed by Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc. in 15-2021 cannot be accepted for filing at this time. Reasons: pdf is not text searchable; no proof of service; attorney is not a registered ECF filer. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [371146] [AT] [Entered: 10/04/2016 07:32 AM] (0) |
| Oct 4, 2016 | 109 | NOTICE OF DEFICIENCY: The attorney entry of appearance for KEVIN E. WARNER, Document No. [106] filed by Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc. in 15-2021 is not signed and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [371147] [AT] [Entered: 10/04/2016 07:34 AM] (0) |
| Oct 4, 2016 | 110 | NOTICE OF DEFICIENCY: The attorney entry of appearance for GEORGE C. LOMBARDI, Document No. [105] filed by Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc. in 15-2021 is not signed and is mis-dated and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [371148] [AT] [Entered: 10/04/2016 07:36 AM] (0) |
| Oct 4, 2016 | 111 | Corrected Entry of appearance for George C. Lombardi as of counsel for Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc.. Service: 10/04/2016 by email. [371300] [George Lombardi] [Entered: 10/04/2016 12:22 PM] (2) |
| Oct 4, 2016 | 112 | Corrected Entry of appearance for Scott R. Samay as of counsel for Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc.. Service: 10/04/2016 by email. [371307] [Scott Samay] [Entered: 10/04/2016 12:28 PM] (2) |
| Oct 4, 2016 | 113 | Corrected Entry of appearance for Kevin E. Warner as of counsel for Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc.. Service: 10/04/2016 by email. [371312] [Kevin Warner] [Entered: 10/04/2016 12:35 PM] (2) |
| Oct 3, 2016 | 103 | TENDERED from Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Title: NOTICE OF JOINDER. Service: 10/03/2016 by email. [371052] [Brian Robinson] [Entered: 10/03/2016 04:13 PM] (4) |
| Oct 3, 2016 | 104 | TENDERED from Appellants Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd. and ThoRx Laboratories, Inc.. Title: OPENING BRIEF. Service: 10/03/2016 by email. [371062] This brief has been rejected for filing. See Doc. No. [114] [Brenda Joly] [Entered: 10/03/2016 04:28 PM] (0) |
| Oct 3, 2016 | 105 | Entry of appearance for George C. Lombardi as of counsel for Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc.. Service: 10/03/2016 by email. [371120] [George Lombardi] [Entered: 10/03/2016 07:00 PM] (2) |
| Oct 3, 2016 | 106 | Entry of appearance for Kevin E. Warner as of counsel for Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc.. Service: 10/03/2016 by email. [371121] [Kevin Warner] [Entered: 10/03/2016 07:07 PM] (2) |
| Oct 3, 2016 | 107 | Entry of appearance for Scott R. Samay as of counsel for Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc.. Service: 10/03/2016 by email. [371124] [Kevin Warner] [Entered: 10/03/2016 07:31 PM] (1) |
| Sep 30, 2016 | 99 | MOTION of Appellants Actavis Inc. and Actavis South Atlantic LLC to file a corrected Opening Brief for Defendants-Appellants Actavis Inc. and Actavis South Atlantic LLC filed on July 29, 2016 (confidential and non-confidential versions) brief. Response/Opposition is due 10/14/2016 [Consent: unopposed]. Service: 09/30/2016 by email. [370705] [Charles Weiss] [Entered: 09/30/2016 06:22 PM] (6) |
| Sep 30, 2016 | 100 | TENDERED from Appellants Actavis Inc. and Actavis South Atlantic LLC. Title: CONFIDENTIAL OPENING BRIEF Service: 09/30/2016 by email, US mail. [370715] This brief has been corrected. See Doc. No. [154] [Charles Weiss] [Entered: 09/30/2016 08:04 PM] (0) |
| Sep 30, 2016 | 101 | TENDERED from Appellants Actavis Inc. and Actavis South Atlantic LLC. Title: OPENING BRIEF. Service: 09/30/2016 by email. [370718] This brief has been corrected. See Doc. No. [155] [Charles Weiss] [Entered: 09/30/2016 08:06 PM] (0) |
| Sep 30, 2016 | 102 | TENDERED from Appellant Watson Pharmaceuticals, Inc.. Title: NOTICE OF JOINDER. Service: 09/30/2016 by email. [370719] [Charles Weiss] [Entered: 09/30/2016 08:08 PM] (4) |
| Sep 29, 2016 | 94 | Entry of appearance for James F. Hurst as of counsel for Appellants Actavis Inc. and Actavis South Atlantic LLC. Service: 09/29/2016 by email. [370315] [William Burgess] [Entered: 09/29/2016 04:07 PM] (1) |
| Sep 29, 2016 | 95 | Corrected Entry of appearance for James F. Hurst as of counsel for Appellants Actavis Inc. and Actavis South Atlantic LLC. Service: 09/29/2016 by email. [370316] [William Burgess] [Entered: 09/29/2016 04:09 PM] (2) |
| Sep 29, 2016 | 96 | Entry of appearance for John C. O'Quinn as of counsel for Appellants Actavis Inc. and Actavis South Atlantic LLC. Service: 09/29/2016 by email. [370317] [William Burgess] [Entered: 09/29/2016 04:10 PM] (2) |
| Sep 29, 2016 | 97 | Entry of appearance for William H. Burgess as of counsel for Appellants Actavis Inc. and Actavis South Atlantic LLC. Service: 09/29/2016 by email. [370318] [William Burgess] [Entered: 09/29/2016 04:10 PM] (2) |
| Sep 29, 2016 | 98 | Amended Certificate of Interest for the Appellants Actavis Inc. and Actavis South Atlantic LLC. Service: 09/29/2016 by email. [370320] [William Burgess] [Entered: 09/29/2016 04:11 PM] (3) |
| Aug 18, 2016 | 91 | Amended Docketing Statement for the Cross-Appellant Endo Pharmaceuticals Inc.. Service: 08/18/2016 by email. [359917] [Martin Black] [Entered: 08/18/2016 11:55 AM] (4) |
| Aug 18, 2016 | 92 | Amended Docketing Statement for the Cross-Appellant Grunenthal Gmbh. Service: 08/18/2016 by email. [360143] [Charles Lipsey] [Entered: 08/18/2016 05:48 PM] (3) |
| Aug 18, 2016 | 93 | Amended Docketing Statement for the Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 08/18/2016 by email. [360170] [Elizabeth Holland] [Entered: 08/18/2016 08:47 PM] (3) |
| Aug 16, 2016 | 90 | Amended Docketing Statement for the Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc.. Service: 08/16/2016 by email. [359154] [Maureen Rurka] [Entered: 08/16/2016 11:34 AM] (3) |
| Aug 11, 2016 | 89 | Amended Docketing Statement for the Appellant Roxane Laboratories, Inc.. Service: 08/11/2016 by email. [358158] [Alan Clement] [Entered: 08/11/2016 03:43 PM] (3) |
| Aug 10, 2016 | 88 | Amended Docketing Statement for the Appellants Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc. and Sun Pharmaceutical Industries, Ltd.. Service: 08/10/2016 by email. [357844] [William Zimmerman] [Entered: 08/10/2016 05:47 PM] (4) |
| Aug 8, 2016 | 87 | Docketing Statement for the Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC. Service: 08/08/2016 by email. [357063] [Brenda Joly] [Entered: 08/08/2016 05:18 PM] (3) |
| Aug 4, 2016 | 79 | ORDER filed reactivating appeals; consolidating appeals (2015-2021, -2022, -2023, -2024, -2025, -2026, -2028, -2031, -2033, -2034, -2035, -2041, -2042, -2046, -2047, -2049, -2059, -2060; 2016-1025, and -1117). The revised official caption is reflected in the order.; The plaintiffs-cross-appellant's brief is due no later than 60 days from the date of filing of this order. Service: 08/04/2016 by clerk. [356104] [15-2021, 15-2022, 15-2023, 15-2024, 15-2025, 15-2026, 15-2028, 15-2031, 15-2033, 15-2034, 15-2035, 15-2041, 15-2042, 15-2046, 15-2047, 15-2049, 15-2059, 15-2060, 16-1025, 16-1117] [NL] [Entered: 08/04/2016 10:35 AM] (0) |
| Aug 4, 2016 | 80 | CORRECTED ORDER: correcting order [79]--This order corrects the following: the parties' appellate designations; 2016-1060, -1118 are added; subparagr. 3). IT IS ORDERED THAT: Appeals 2015-2021, et al., are reactivated. Appeals 2015-2021, et al., and 2016-1025, -1117 are consolidated. Revised official caption is reflected in the order. Appellants' opening briefs are due within 60 days. Service as of this date by Clerk of Court. [356231] [AT] [Entered: 08/04/2016 02:46 PM] (3) |
| Aug 4, 2016 | 81 | Note to file: LEAD APPEAL 2015-2021 is consolidated with appeals 2016-1025, -1117. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [356253] [AT] [Entered: 08/04/2016 03:04 PM] (0) |
| Aug 4, 2016 | 82 | Official caption revised pursuant to the court's order filed 8/4/16. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [356275] [AT] [Entered: 08/04/2016 03:26 PM] (0) |
| Jul 29, 2016 | 83 | TENDERED from Appellants Actavis Inc. and Actavis South Atlantic LLC. Title: OPENING BRIEF. [CLERK'S NOTE: This brief has been transferred to this docket from the docket for 2016-1025. See the court's order filed 8/4/16]. [356288] This brief will not be transmitted to the merits panel pursuant to this court's October 5, 2016 order. [116] [AT] [Entered: 08/04/2016 03:46 PM] (0) |
| Jul 29, 2016 | 84 | TENDERED from Appellants Actavis Inc. and Actavis South Atlantic LLC. Title: CONFIDENTIAL OPENING BRIEF [CLERK'S NOTE: This brief has been transferred to this docket from the docket for 2016-1025. See the court's order filed 8/4/16] [356289] This brief will not be transmitted to the merits panel pursuant to this court's October 5, 2016 order. [116] [AT] [Entered: 08/04/2016 03:48 PM] (0) |
| Jul 29, 2016 | 85 | BRIEF FILED for Appellants Actavis Inc. and Actavis South Atlantic LLC [83]. Number of Pages: 61. Service: 07/29/2016 by email. [CLERK'S NOTE: This brief has been transferred to this docket from the docket for 2016-1025. See the court's order filed 8/4/16] [356295] This brief will not be transmitted to the merits panel pursuant to this court's October 5, 2016 order. [116] [AT] [Entered: 08/04/2016 03:51 PM] (0) |
| Jul 29, 2016 | 86 | CONFIDENTIAL BRIEF FILED for Appellants Actavis Inc. and Actavis South Atlantic LLC [84]. Number of Pages: 61. Service: 07/29/2016 by US mail. [CLERK'S NOTE: This brief has been transferred to this docket from the docket for 2016-1025. See the court's order filed 8/4/16] [356296] This brief will not be transmitted to the merits panel pursuant to this court's October 5, 2016 order. [116] [AT] [Entered: 08/04/2016 03:53 PM] (0) |
| Jul 22, 2016 | 77 | Entry of appearance for Brenda L. Joly as of counsel for Cross-Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC. Service: 07/22/2016 by email. [352942] [Brenda Joly] [Entered: 07/22/2016 01:22 PM] (2) |
| Jul 22, 2016 | 78 | Status report for Cross-Appellants Actavis Inc., Actavis South Atlantic LLC, Amneal Pharmaceuticals of New York, LLC, Amneal Pharmaceuticals, LLC, Barr Laboratories, Inc., Impax Laboratories, Inc., Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc., Roxane Laboratories, Inc., Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc. and Watson Pharmaceuticals, Inc.. Service: 07/22/2016 by email. [352953] [Brenda Joly] [Entered: 07/22/2016 01:43 PM] (6) |
| Jul 12, 2016 | 76 | Amended Notice of Appeal for Grunenthal GMBH. Service: 07/12/2016 by email. [350108] [SJ] [Entered: 07/12/2016 11:17 AM] (273) |
| Jul 11, 2016 | 75 | Letter from Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh Reactivating Appeals and Requesting Consolidation. Service: 07/11/2016 by email. [349744] [Martin Black] [Entered: 07/11/2016 12:38 PM] (9) |
| Jun 6, 2016 | 74 | Amended Notice of Appeal for Endo Pharmaceuticals (1:13-cv-03288-TPG). Service: 06/06/2016 by email. [342034] [SJ] [Entered: 06/09/2016 08:36 AM] (57) |
| Jun 2, 2016 | 73 | Amended Notice of Appeal (to 16-1060) for Roxane Laboratories, Inc. Service: 06/01/2016 by email. [340320] [SJ] [Entered: 06/02/2016 02:03 PM] (71) |
| May 26, 2016 | 72 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account(s) of Mr. Hugh S. Balsam, Esq. and Alan B. Clement for Roxane Laboratories, Inc. The e-mail address, (skruczek@lockelord.com), associated with your CM/ECF accounts has generated a delivery failure notice. Pursuant to Fed. Cir. R. 47.3(c)(1), counsel should promptly update their account information with the Pacer Service Center. [338743] [IW] [Entered: 05/26/2016 12:41 PM] (0) |
| May 4, 2016 | 71 | Status report for Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh. Service: 05/04/2016 by email. [332320] [Charles Lipsey] [Entered: 05/04/2016 05:23 PM] (37) |
| Mar 15, 2016 | 70 | Amended Certificate of Interest for the Cross-Appellant Roxane Laboratories, Inc.. Service: 03/15/2016 by email. [318713] [Alan Clement] [Entered: 03/15/2016 12:37 PM] (3) |
| Oct 29, 2015 | 66 | Docketing Statement for the Appellant Endo Pharmaceuticals Inc.. Service: 10/29/2015 by email. [284621] [Sharon Gagliardi] [Entered: 10/29/2015 04:25 PM] (3) |
| Oct 29, 2015 | 67 | Docketing Statement for the Cross-Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 10/29/2015 by email. [284642] [Elizabeth Holland] [Entered: 10/29/2015 04:41 PM] (3) |
| Oct 29, 2015 | 68 | Docketing Statement for the Cross-Appellants Actavis Inc., Actavis South Atlantic LLC and Watson Pharmaceuticals, Inc.. Service: 10/29/2015 by email. [284650] [Charles Weiss] [Entered: 10/29/2015 04:58 PM] (4) |
| Oct 29, 2015 | 69 | Certificate of Interest for the Cross-Appellants Actavis Inc., Actavis South Atlantic LLC and Watson Pharmaceuticals, Inc.. Service: 10/29/2015 by email. [284651] [Charles Weiss] [Entered: 10/29/2015 05:09 PM] (3) |
| Oct 28, 2015 | 63 | Notice to counsel for Appellant Endo Pharmaceuticals Inc. and Cross-Appellants Actavis Inc., Actavis South Atlantic LLC, Barr Laboratories, Inc., Roxane Laboratories, Inc., Teva Pharmaceuticals USA, Inc., ThoRx Laboratories, Inc. and Watson Pharmaceuticals, Inc.: The record of this case indicates that either a Docketing Statement or Certificate of Interest has not been filed. A completed certificate of Interest must be submitted in accordance with Fed. Cir. R. 47.4 by 10/29/2015. Docketing Statement due 10/29/2015. Service as of this date by Clerk of Court. [283926] [JW] [Entered: 10/28/2015 09:02 AM] (0) |
| Oct 28, 2015 | 64 | Certificate of Interest for the Cross-Appellant Roxane Laboratories, Inc.. Service: 10/28/2015 by email. [284206] [Hugh Balsam] [Entered: 10/28/2015 04:58 PM] (3) |
| Oct 28, 2015 | 65 | Docketing Statement for the Cross-Appellant Roxane Laboratories, Inc.. Service: 10/28/2015 by email. [284207] [Hugh Balsam] [Entered: 10/28/2015 05:00 PM] (3) |
| Oct 26, 2015 | 61 | Note to file: The following cases are associated:15-2021 (lead) with 16-1118 (consol.). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [283310] [15-2021, 16-1118] [SJ] [Entered: 10/26/2015 10:05 AM] (0) |
| Oct 26, 2015 | 62 | Official caption revised to add appeal of Endo Pharma. in 13-cv-8597. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [283312] [SJ] [Entered: 10/26/2015 10:06 AM] (0) |
| Oct 19, 2015 | 60 | Docketing Statement for the Cross-Appellants Impax Laboratories, Inc. and ThoRx Laboratories, Inc.. Service: 10/19/2015 by email. [281387] [Maureen Rurka] [Entered: 10/19/2015 12:30 PM] (3) |
| Oct 13, 2015 | 58 | Note to file: The following cases are associated:15-2021 (lead) with 16-1060. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [279780] [15-2021, 16-1060] [SJ] [Entered: 10/13/2015 12:01 PM] (0) |
| Oct 13, 2015 | 59 | Official caption revised to add appeal of Endo Pharma. in 13-cv-3288. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [279781] [SJ] [Entered: 10/13/2015 12:01 PM] (0) |
| Oct 9, 2015 | 53 | Entry of appearance for Elizabeth J. Holland as principal counsel for Cross-Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 10/09/2015 by email. [279268] [Elizabeth Holland] [Entered: 10/09/2015 12:02 PM] (3) |
| Oct 9, 2015 | 54 | Entry of appearance for Brian J. Robinson as of counsel for Cross-Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 10/09/2015 by email. [279274] [Brian Robinson] [Entered: 10/09/2015 12:07 PM] (3) |
| Oct 9, 2015 | 55 | Entry of appearance for Huiya Wu as of counsel for Cross-Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 10/09/2015 by email. [279278] [Huiya Wu] [Entered: 10/09/2015 12:10 PM] (3) |
| Oct 9, 2015 | 56 | Certificate of Interest for the Cross-Appellants Barr Laboratories, Inc. and Teva Pharmaceuticals USA, Inc.. Service: 10/09/2015 by email. [279279] [Elizabeth Holland] [Entered: 10/09/2015 12:13 PM] (2) |
| Oct 9, 2015 | 57 | Entry of appearance for Blake B. Greene as of counsel for Appellant Endo Pharmaceuticals Inc.. Service: 10/09/2015 by email. [279335] [Blake Greene] [Entered: 10/09/2015 01:43 PM] (6) |
| Oct 7, 2015 | 52 | Official caption revised to amend case consolidation. Appeal 16-1025 is a stand-alone matter. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [278255] [15-2021, 16-1025] [SJ] [Entered: 10/07/2015 08:33 AM] (0) |
| Oct 6, 2015 | 49 | This entry was made in error and has been removed from the docket. Note to file: The following cases are associated:15-2021 (lead) with 16-1025 (cross-appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [278211] [15-2021, 16-1025] [SJ] [Entered: 10/06/2015 04:49 PM] (0) |
| Oct 6, 2015 | 50 | This entry was made in error and has been removed from the docket. MOTION of Cross-Appellants Actavis Inc. and Actavis South Atlantic LLC for an emergency stay pending appeal under Rule 8 [Consent: opposed]. Service: 10/06/2015 by US mail. [278219] [SJ] [Entered: 10/06/2015 04:58 PM] (0) |
| Oct 6, 2015 | 51 | This entry was made in error and has been removed from the docket. Sealed or confidential document received [confidential rule 8 motion and exhibits] (corresponding to Doc No. [50]) for Cross-Appellants Actavis Inc. and Actavis South Atlantic LLC. Service: 10/06/2015 by US mail. [278220] [SJ] [Entered: 10/06/2015 05:01 PM] (0) |
| Oct 2, 2015 | 48 | CLERK'S OFFICE QUALITY CONTROL MESSAGE: Notice regarding the ECF account(s) of Jamie R. Kurtz for Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC. An e-mail address associated with your CM/ECF account, (ljpeterson@rkmc.com), is invalid and has been returned as undeliverable. Pursuant to ECF-2(E) of the Administrative Order Regarding Electronic Case Filing, an ECF filer must update all contact information with the Pacer Service Center. Counsel should promptly update her account information with the Pacer Service Center at www.pacer.gov. [277001] [IW] [Entered: 10/02/2015 07:32 AM] (0) |
| Oct 1, 2015 | 43 | Entry of appearance for Eric H. Yecies as principal counsel for Cross-Appellants Actavis Inc., Actavis South Atlantic LLC and Watson Pharmaceuticals, Inc.. Service: 10/01/2015 by email. [276933] [Eric Yecies] [Entered: 10/01/2015 04:48 PM] (1) |
| Oct 1, 2015 | 44 | Entry of appearance for Charles A. Weiss as principal counsel for Cross-Appellants Actavis Inc., Actavis South Atlantic LLC and Watson Pharmaceuticals, Inc.. Service: 10/01/2015 by email. [276937] [Charles Weiss] [Entered: 10/01/2015 04:55 PM] (1) |
| Oct 1, 2015 | 45 | Certificate of Interest for the Cross-Appellants Actavis Inc., Actavis South Atlantic LLC and Watson Pharmaceuticals, Inc.. Service: 10/01/2015 by email. [276938] [Charles Weiss] [Entered: 10/01/2015 04:57 PM] (2) |
| Oct 1, 2015 | 46 | Entry of appearance for Nicholas P. Chiara as of counsel for Cross-Appellants Actavis Inc., Actavis South Atlantic LLC and Watson Pharmaceuticals, Inc.. Service: 10/01/2015 by email. [276942] [Nicholas Chiara] [Entered: 10/01/2015 05:04 PM] (1) |
| Oct 1, 2015 | 47 | CORRECTED ENTRY: CORRECTED certificate of service for Cross-Appellants Actavis Inc., Actavis South Atlantic LLC and Watson Pharmaceuticals, Inc. for attorney entry of appearance Doc No. [46], certificate of interest Doc No. [45], attorney entry of appearance Doc No. [44], attorney entry of appearance Doc No. [43]. Service: 10/01/2015 by email. [276943] --[Edited 10/02/2015 by clerk - Reason: incorrect event was used] [Nicholas Chiara] [Entered: 10/01/2015 05:09 PM] (2) |
| Sep 29, 2015 | 41 | NOTICE OF DEFICIENCY: The docketing statement Document No. [33] filed by Cross-Appellants Amneal Pharmaceuticals, LLC and Amneal Pharmaceuticals of New York, LLC in 15-2021 is submitted using an incorrect docket number and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [275834] [JW] [Entered: 09/29/2015 08:48 AM] (0) |
| Sep 29, 2015 | 42 | Docketing Statement for the Appellant Grunenthal Gmbh. Service: 09/29/2015 by email. [276217] [Charles Lipsey] [Entered: 09/29/2015 05:36 PM] (3) |
| Sep 28, 2015 | 34 | Entry of appearance for Alan B. Clement as principal counsel for Cross-Appellant Roxane Laboratories, Inc.. Service: 09/28/2015 by email. [275673] [Hugh Balsam] [Entered: 09/28/2015 02:54 PM] (3) |
| Sep 28, 2015 | 35 | Entry of appearance for Myoka Kim Goodin as of counsel for Cross-Appellant Roxane Laboratories, Inc.. Service: 09/28/2015 by email. [275674] [Hugh Balsam] [Entered: 09/28/2015 02:55 PM] (3) |
| Sep 28, 2015 | 36 | Entry of appearance for Scott B. Feder as of counsel for Cross-Appellant Roxane Laboratories, Inc.. Service: 09/28/2015 by email. [275675] [Hugh Balsam] [Entered: 09/28/2015 02:56 PM] (3) |
| Sep 28, 2015 | 37 | Entry of appearance for Hugh S. Balsam as of counsel for Cross-Appellant Roxane Laboratories, Inc.. Service: 09/28/2015 by email. [275676] [Hugh Balsam] [Entered: 09/28/2015 02:57 PM] (3) |
| Sep 28, 2015 | 38 | Entry of appearance for Robert D. Rhoad as of counsel for Appellant Endo Pharmaceuticals Inc.. Service: 09/28/2015 by email. [275755] [Sharon Gagliardi] [Entered: 09/28/2015 04:10 PM] (6) |
| Sep 28, 2015 | 39 | Entry of appearance for Jonathan D. Loeb as of counsel for Appellant Endo Pharmaceuticals Inc.. Service: 09/28/2015 by email. [275756] [Sharon Gagliardi] [Entered: 09/28/2015 04:11 PM] (6) |
| Sep 28, 2015 | 40 | Entry of appearance for Sharon K. Gagliardi as of counsel for Appellant Endo Pharmaceuticals Inc.. Service: 09/28/2015 by email. [275758] [Sharon Gagliardi] [Entered: 09/28/2015 04:12 PM] (6) |
| Sep 25, 2015 | 33 | Corrected Docketing Statement for the Cross-Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC. Service: 09/25/2015 by email. [275380] [Jacob Holdreith] [Entered: 09/25/2015 03:12 PM] (0) |
| Sep 24, 2015 | 20 | Entry of appearance for Charles E. Lipsey as principal counsel for Appellant Grunenthal Gmbh. Service: 09/23/2015 by email. [274577] [Charles Lipsey] [Entered: 09/23/2015 01:35 PM] (2) |
| Sep 24, 2015 | 21 | Certificate of Interest for the Appellant Grunenthal Gmbh. Service: 09/23/2015 by email. [274578] [Charles Lipsey] [Entered: 09/23/2015 01:36 PM] (3) |
| Sep 24, 2015 | 22 | Entry of appearance for Jennifer H. Roscetti as of counsel for Appellant Grunenthal Gmbh. Service: 09/23/2015 by email. [274579] [Charles Lipsey] [Entered: 09/23/2015 01:37 PM] (2) |
| Sep 24, 2015 | 23 | Entry of appearance for Erin M. Sommers as of counsel for Appellant Grunenthal Gmbh. Service: 09/23/2015 by email. [274580] [Charles Lipsey] [Entered: 09/23/2015 01:38 PM] (2) |
| Sep 24, 2015 | 24 | Corrected Entry of appearance for Maureen Rurka as principal counsel for Appellee Impax Laboratories, Inc. ThoRx Laboratories, Inc.. Service: 09/24/2015 by email. [274696] [Maureen Rurka] [Entered: 09/24/2015 09:49 AM] (2) |
| Sep 24, 2015 | 25 | Corrected Certificate of Interest for the Appellee Impax Laboratories, Inc.. Service: 09/24/2015 by email. [274700] [Maureen Rurka] [Entered: 09/24/2015 09:51 AM] (2) |
| Sep 24, 2015 | 26 | Note to file: The following cases are associated:15-2021 (lead) with 15-2059 & 15-2060 (cross-appeals). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [274766] [15-2021, 15-2059, 15-2060] [SJ] [Entered: 09/24/2015 11:41 AM] (0) |
| Sep 24, 2015 | 27 | Official caption revised to add cross-appeals by Impax. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [274767] [SJ] [Entered: 09/24/2015 11:44 AM] (0) |
| Sep 24, 2015 | 28 | ORDER filed. These appeals are deactivated. Within 30 days of the district court's ruling on Plaintiffs' Rule 60(a) motion, the parties are directed to inform this court how they believe these appeals should proceed. Service: 09/24/2015 by clerk. [274852] [15-2021, 15-2022, 15-2023, 15-2024, 15-2025, 15-2026, 15-2028, 15-2031, 15-2033, 15-2034, 15-2035, 15-2041, 15-2042, 15-2046, 15-2047, 15-2049, 15-2059, 15-2060] [LMS] [Entered: 09/24/2015 02:20 PM] (2) |
| Sep 24, 2015 | 29 | Entry of appearance for William R. Zimmerman as principal counsel for Cross-Appellants Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc. and Sun Pharmaceutical Industries, Ltd.. Service: 09/24/2015 by email. [275005] [William Zimmerman] [Entered: 09/24/2015 04:52 PM] (2) |
| Sep 24, 2015 | 30 | Certificate of Interest for the Cross-Appellants Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc. and Sun Pharmaceutical Industries, Ltd.. Service: 09/24/2015 by email. [275008] [William Zimmerman] [Entered: 09/24/2015 04:53 PM] (2) |
| Sep 24, 2015 | 31 | Docketing Statement for the Cross-Appellants Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc. and Sun Pharmaceutical Industries, Ltd.. Service: 09/24/2015 by email. [275010] [William Zimmerman] [Entered: 09/24/2015 04:55 PM] (4) |
| Sep 24, 2015 | 32 | Entry of appearance for Carol Pitzel Cruz as of counsel for Cross-Appellants Ranbaxy Pharmaceuticals, Inc., Ranbaxy, Inc. and Sun Pharmaceutical Industries, Ltd.. Service: 09/24/2015 by email. [275015] [Carol Pitzel Cruz] [Entered: 09/24/2015 05:00 PM] (2) |
| Sep 22, 2015 | 12 | NOTICE OF DEFICIENCY: The certificate of interest Document No. [11] filed by Appellee Impax Laboratories, Inc. in 15-2021 , attorney entry of appearance Document No. [10] filed by Appellee Impax Laboratories, Inc. in 15-2021 is without a proper/complete proof of service and therefore cannot be accepted for filing at this time. You are being afforded the opportunity to correct the deficiency. At the discretion of the court, the corrected document may be accepted for filing if received before midnight (EST) on the date of this notice. [274201] [JW] [Entered: 09/22/2015 10:16 AM] (0) |
| Sep 22, 2015 | 13 | Entry of appearance for Jake M. Holdreith as principal counsel for Cross-Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC. Service: 09/22/2015 by email. [274441] [Jacob Holdreith] [Entered: 09/22/2015 03:01 PM] (3) |
| Sep 22, 2015 | 14 | Entry of appearance for Jamie R. Kurtz as of counsel for Cross-Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC. Service: 09/22/2015 by email. [274442] [Jacob Holdreith] [Entered: 09/22/2015 03:03 PM] (3) |
| Sep 22, 2015 | 15 | Entry of appearance for Oren D. Langer as of counsel for Cross-Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC. Service: 09/22/2015 by email. [274445] [Jacob Holdreith] [Entered: 09/22/2015 03:04 PM] (4) |
| Sep 22, 2015 | 16 | Certificate of Interest for the Cross-Appellants Amneal Pharmaceuticals of New York, LLC and Amneal Pharmaceuticals, LLC. Service: 09/22/2015 by email. [274446] [Jacob Holdreith] [Entered: 09/22/2015 03:04 PM] (4) |
| Sep 22, 2015 | 17 | Certificate of Interest for the Appellant Endo Pharmaceuticals Inc.. Service: 09/22/2015 by email. [274516] [Sharon Gagliardi] [Entered: 09/22/2015 04:55 PM] (7) |
| Sep 22, 2015 | 18 | Entry of appearance for Martin J. Black as principal counsel for Appellant Endo Pharmaceuticals Inc.. Service: 09/22/2015 by email. [274518] [Sharon Gagliardi] [Entered: 09/22/2015 04:56 PM] (6) |
| Sep 22, 2015 | 19 | Letter from Appellants Endo Pharmaceuticals Inc. and Grunenthal Gmbh Notice Per Rule 4 Regarding Post Judgment Motions. Service: 09/22/2015 by email. [274521] [Sharon Gagliardi] [Entered: 09/22/2015 04:58 PM] (18) |
| Sep 21, 2015 | 10 | Entry of appearance for Maureen L. Rurka as principal counsel for Appellee Impax Laboratories, Inc. ThoRx Laboratories, Inc.. Service: 09/21/2015 by email. [274084] [Maureen Rurka] [Entered: 09/21/2015 05:50 PM] (0) |
| Sep 21, 2015 | 11 | Certificate of Interest for the Appellee Impax Laboratories, Inc.. Service: 09/21/2015 by email. [274086] [Maureen Rurka] [Entered: 09/21/2015 05:52 PM] (0) |
| Sep 18, 2015 | 8 | Note to file: The following cases are associated:15-2021 (lead) with 15-2046, 15-2047, and 15-2049. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [273529] [15-2021, 15-2046, 15-2047, 15-2049] [SJ] [Entered: 09/18/2015 02:48 PM] (0) |
| Sep 18, 2015 | 9 | Official caption revised to add 3 additional appeals. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [273532] [SJ] [Entered: 09/18/2015 02:52 PM] (0) |
| Sep 17, 2015 | 6 | Note to file: The following cases are associated:15-2021 (lead) with 15-2042 (cross-appeal). FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [272965] [15-2021, 15-2042] [SJ] [Entered: 09/17/2015 10:03 AM] (0) |
| Sep 17, 2015 | 7 | Official caption revised to add cross-appeal by Teva & Barr. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [273047] [SJ] [Entered: 09/17/2015 10:12 AM] (0) |
| Sep 16, 2015 | 4 | Note to file: The following cases are associated: LEAD APPEAL 2015-2021 and cross-appeal 2015-2041 [filed by Amneal Pharmaceuticals]. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [272831] [AT] [Entered: 09/16/2015 03:45 PM] (0) |
| Sep 16, 2015 | 5 | Official caption revised to add the cross appeal filed by the Amneal Pharmaceuticals parties [docketed as no. 15-2041]. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [272834] [AT] [Entered: 09/16/2015 03:46 PM] (0) |
| Sep 15, 2015 | 1 | Appeal docketed. Received: 09/14/2015. [272185]Entry of Appearance due 09/29/2015. Certificate of Interest is due on 09/29/2015. Docketing Statement due 09/29/2015. Appellant/Petitioner's brief is due 11/16/2015. [SJ] [Entered: 09/15/2015 10:39 AM] (231) |
| Sep 15, 2015 | 2 | Note to file: The following cases are associated:15-2021 (lead) with 15-2022, -2023, -2024, -2025, -2026, -2028, -2031, -2033, -2034, -2035. FURTHER ENTRIES WILL BE ADDED TO THE LEAD APPEAL ONLY. [272323] [15-2021, 15-2022, 15-2023, 15-2024, 15-2025, 15-2026, 15-2028, 15-2031, 15-2033, 15-2034, 15-2035] [SJ] [Entered: 09/15/2015 12:55 PM] (0) |
| Sep 15, 2015 | 3 | Official caption revised to add additional appeals. The official caption is reflected on the electronic docket under the listing of the parties and counsel. Service as of this date by Clerk of Court. [272334] [SJ] [Entered: 09/15/2015 01:12 PM] (0) |
